down arrow

ANG Lifesciences

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE236W01016
  • NSEID:
  • BSEID: 540694
INR
29.34
-0.15 (-0.51%)
BSENSE

Apr 11, 12:46 PM

BSE+NSE Vol: 2.11 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Divi's Lab.
Cipla
Sun Pharma.Inds.
Torrent Pharma
Mankind Pharma
Concord Drugs
ANG Lifesciences
Vineet Laborator
Dipna Pharmachem
Panjon
Vilin Bio Med
Why is ANG Lifesciences India Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of -35.75% and Operating profit at -144.55% over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 52.88 times
2
The company has declared Negative results for the last 11 consecutive quarters
  • NET SALES(9M) At Rs 76.02 cr has Grown at -29.79%
  • PAT(9M) At Rs -10.35 cr has Grown at -29.79%
  • ROCE(HY) Lowest at -2.25%
3
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 06-Jan-25 and has generated -35.22% returns since then
  • The stocks MACD and KST technical factors are also Bearish
4
Risky - Negative Operating Profits
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -52.60%, its profits have fallen by -10.4%
5
44.88% of Promoter Shares are Pledged
  • In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ANG Lifesciences for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
ANG Lifesciences
-50.47%
-1.19
44.19%
SENSEX
0.45%
0.03
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-35.75%
EBIT Growth (5y)
-144.55%
EBIT to Interest (avg)
2.20
Debt to EBITDA (avg)
21.72
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.34
Tax Ratio
11.89%
Dividend Payout Ratio
0
Pledged Shares
44.88%
Institutional Holding
0
ROCE (avg)
9.07%
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
0.54
EV to EBIT
-21.43
EV to EBITDA
67.43
EV to Capital Employed
0.79
EV to Sales
1.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.48%
ROE (Latest)
-18.26%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
NET SALES(Q)

At Rs 24.73 cr has Grown at 33.32%

-15What is not working for the Company
NET SALES(9M)

At Rs 76.02 cr has Grown at -29.79%

PAT(9M)

At Rs -10.35 cr has Grown at -29.79%

ROCE(HY)

Lowest at -2.25%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.03 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.55 times

OPERATING PROFIT TO INTEREST (Q)

Lowest at -1.08 times

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 3.96 cr

DEBT-EQUITY RATIO(HY)

Highest at 1.20 times

PBDIT(Q)

Lowest at Rs -2.15 cr.

Loading Valuation Snapshot...
Here's what is working for ANG Lifesciences
Net Sales - Quarterly
At Rs 24.73 cr has Grown at 33.32%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for ANG Lifesciences
Operating Profit to Interest - Quarterly
Lowest at -1.08 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Inventory Turnover Ratio- Half Yearly
Lowest at 2.03 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio- Half Yearly
Lowest at 1.55 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Profit After Tax (PAT) - Nine Monthly
At Rs -10.35 cr has Grown at -29.79%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is negative

PAT (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs -2.15 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 3.96 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio - Half Yearly
Highest at 1.20 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio